Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib-Containing Regimen for Hemophagocytic Lymphohistiocytosis
NCT04551131Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in hemophagocytic lymphohistiocytosis (HLH) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Complete Response/Complete Response with Incomplete Hematologic Recovery at 8 weeks and Adverse Events at 1 year. Started Jul 2021; status: active, not recruiting.
02
Drugs
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT04551131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551131.